CAR-T cell therapy is as a type of immunotherapy that teaches T cells to recognize and destroy cancer. CAR-T cell therapy has demonstrated promising results in a range of patients from young and old. In some patients, this can lead to the total elimination of the cancer. In others, there is a significant improvement of the disease.

For those who are facing cancer, it is important to answer the question “What is CAR-T?” This guide will answer the most common questions about CAR-T cell therapy for readers who want to understand this novel technology platform for treating cancer.  [Read more…]

What is CAR-T therapy? Chimeric antigen receptor T-cell (CAR-T) therapy is a targeted approach to treating cancer that uses a patient’s T cells, which are a type of immune system cell.

Since the first CAR-T therapy approvals in 2017 by the U.S. FDA, CAR-T deal-making has attracted vast sums of money. This article summarizes recent partnerships and deal-making with the CAR-T marketplace. [Read more…]

Learn more about innovative CAR-T cell therapy companies and the technologies they use to fight cancer. This article lists 100+ of the leading CAR-T therapy companies worldwide.

In this article:

1. 1. An Introduction to CAR-T Companies
   2. Chimeric Antigen Receptors
   3. Increase in CAR-T Biotech Companies
   4. List of CAR-T Cell Therapy Companies
   5. Swell of CAR-T Companies

The Leaders of the CAR-T Industry

An Introduction to CAR-T Companies

Chimeric antigen receptor T-cell therapy (CAR-T) is an approach that is now being explored as an alternative to conventional treatments for several forms of cancer. Thus, CAR-T companies are on the rise, supported by a growing investment flowing into CAR-T research, landmark approvals of CAR-T cell therapies Kymriah and Yescarta, and major acquisitions within the CAR-T space. Most notably, Celgene snagged Juno Therapeutics for a shocking $9 billion in January 2018, and Gilead acquired Kite Pharma for an astounding $11.9 billion in August 2017. [Read more…]